Prot #M20-638: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCCORE™ FL-1)

Project: Research project

Project Details

StatusActive
Effective start/end date10/12/2310/12/24

Funding

  • AbbVie Inc. (Prot #M20-638)